Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease [1,2]. Therefore, the evaluation of the prognostic risk is clinically important for AML patients to determine the appropriate therapeutic strategy. The Medical Research Council (MRC) developed the cytogenetic classification system in 1998, and it was refined by considering the clinical characteristics and prognostic relevance of rare cytogenetic abnormalities [3,4]. The refined MRC system, in which three cytogenetic risk groups are distinguished, is widely used for cytogenetic risk stratification of younger adults with AML.

Source: Leukemia Research - January 15, 2018 Category: Hematology Authors: Yasuhiko Harada, Yasunobu Nagata, Rika Kihara, Yuichi Ishikawa, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Shinichi Kobayashi, Kunio Kitamura, Emiko Tags: Research paper Source Type: research